Digital therapeutics for Substance Use Disorders: Research priorities and clinical validation
| Autor: | Kevin M. Walton, Will M. Aklin, Patrick Antkowiak |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry Substance-Related Disorders Public health Research Toxicology Psychiatry and Mental health Incentive Drug control Pandemic Health care medicine Humans Pharmacology (medical) Substance use Intensive care medicine business Reimbursement |
| Zdroj: | Drug and alcohol dependence. 229 |
| ISSN: | 1879-0046 |
| Popis: | Substance Use Disorders (SUDs) have a substantial adverse impact in the United States, with more than $700 billion annually in health care expenditures and lost earnings. 1 The incidence is widespread; approximately 21.6 million individuals over the age of 12 experience substance use or dependence. 1 There are safe and effective FDA approved pharmacological treatments for opioid and nicotine use disorders, but long-term SUD treatment remains challenging. Similarly, despite available efficacious behavioral therapies for SUDs delivered in-person by trained professionals, relapse rates are high. As evidenced during the COVID-19 pandemic, traditional methods of delivering treatment have limitations and can be difficult or even impossible to access. Therefore, additional treatments for SUDs are urgently needed. Digital therapeutics (DTx) represent a new opportunity to address this significant public health challenge and were recently identified by the White House Office of National Drug Control Policy (ONDCP) in the priority to expand access to evidence-based treatment including “reimbursement for motivation incentives and digital treatment for addiction.” |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect